BJDX
Bluejay Diagnostics, Inc.
NASDAQ · USHealthcareMedical - Devices
$1.21-16.55%
Price as of Jul 20, 2026
BJDX growth
Bluejay Diagnostics, Inc. growth
Reported trailing growth, forward expectations and three-year compound growth rates.
Trailing growth
Year over year
- Revenue
- —
- EBITDA
- -7.9%
- EBIT
- -5.6%
- EPS
- +97.1%
- Free cash flow
- +4.7%
- Operating cash flow
- +3.7%
Forward estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- —
- EBITDA
- +0.3%
- EBIT
- +3.0%
- Net income
- +11.3%
- EPS
- +96.7%
- Free cash flow
- +23.4%
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.